Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00939978

Enrollment

Registered

2009-07-15

Start date

2009-04-30

Completion date

2010-07-31

Last updated

2010-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery

Brief summary

The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.

Interventions

DRUGrhEPO

recombinant human erythropoietin(rhEPO)

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* The 90 patients who are planned to have the heart surgery during this study period.(minimum age 20)

Exclusion criteria

* Uncontrolled hypertension(diastolic blood pressure(DBP)\>100 mmHg), Hct \> 45%, Plt. count)\>450,000 * There are no history of seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis. * No pregnancy, acute hyper parathyroidism.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026